Ser130

Site Information
sGEQAEGsPGGPGDs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 455618
Available spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 15 ) , [32P] ATP in vitro ( 3 ) , [32P] bio-synthetic labeling ( 26 , 29 ) , immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 16 , 17 , 18 , 22 , 24 , 25 ) , mutation of modification site ( 3 , 5 , 15 , 21 , 23 , 26 , 27 , 29 ) , phospho-antibody ( 3 , 20 , 26 ) , phosphopeptide mapping ( 29 ) , western blotting ( 3 , 20 , 23 , 26 , 27 )
Disease tissue studied:	bone cancer ( 20 , 26 , 27 ) , osteosarcoma ( 20 ) , breast cancer ( 7 ) , colorectal cancer ( 3 , 5 , 15 , 23 , 29 ) , colorectal carcinoma ( 3 , 5 , 15 , 23 , 29 ) , lung cancer ( 8 , 9 , 10 , 11 , 12 ) , non-small cell lung cancer ( 9 , 10 , 11 , 14 , 16 , 17 ) , non-small cell lung adenocarcinoma ( 9 , 10 , 11 , 12 ) , non-small cell large cell lung carcinoma ( 10 ) , small-cell lung cancer ( 8 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 22 ) , 293 (epithelial) ( 21 , 23 ) , 3T3 (fibroblast) ( 21 , 26 ) , A549 (pulmonary) ( 9 , 16 ) , Cal-12T (pulmonary) ( 11 ) , CHO (fibroblast) ( 15 ) , DMS53 (pulmonary) ( 8 ) , endothelial-aorta ( 18 ) , HCC44 (pulmonary) ( 11 ) , HCT116 (intestinal) ( 3 , 5 , 15 , 23 ) , HD3 ( 29 ) , HeLa (cervical) ( 3 , 6 , 23 , 24 , 25 , 27 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 7 ) , HMLER ('stem, breast cancer') ( 7 ) , lung ( 8 , 9 , 10 , 11 , 12 ) , MG63 (bone cell) ( 20 ) , NCI-H1299 (pulmonary) ( 10 ) , NCI-H1355 (pulmonary) ( 9 ) , NCI-H1437 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H1734 (pulmonary) ( 10 ) , NCI-H1792 (pulmonary) ( 9 ) , NCI-H1944 (pulmonary) ( 10 ) , NCI-H23 (pulmonary) ( 9 ) , NCI-H2405 (pulmonary) ( 11 ) , NCI-H3122 (pulmonary) ( 14 ) , NCI-H3255 (pulmonary) ( 17 ) , NCI-H358 (pulmonary) ( 10 ) , NCI-H441 (pulmonary) ( 9 ) , NCI-H446 (pulmonary) ( 8 ) , NCI-H460 (pulmonary) ( 10 ) , NCI-H526 (pulmonary) ( 8 ) , NCI-H69 (pulmonary) ( 8 ) , NCI-H82 (pulmonary) ( 8 ) , Saos-2 (bone cell) ( 20 , 27 ) , U2OS (bone cell) ( 20 , 26 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Regulatory protein:	CDK4 (human) ( 15 ) , CDK6 (human) ( 26 )
Putative in vivo kinases:	CDK1 (human) ( 3 ) , CDK2 (human) ( 27 ) , ERK2 (human) ( 23 ) , JNK1 (human) ( 29 ) , P38A (human) ( 20 , 29 )
Kinases, in vitro:	CDK1 (human) ( 3 ) , CDK2 (human) ( 15 , 27 , 28 ) , CDK4 (human) ( 15 ) , CDK6 (human) ( 15 , 26 ) , ERK1 (human) ( 2 ) , ERK2 (human) ( 2 , 23 ) , JNK1 (human) ( 2 , 29 ) , JNK2 (human) ( 2 ) , JNK3 (human) ( 2 ) , P38A (human) ( 2 , 29 )
Treatments:	1NM-PP1 ( 15 ) , EGF ( 23 ) , MG132 ( 15 ) , neferine ( 20 ) , PD0332991 ( 15 ) , SB203580 ( 20 ) , seliciclib ( 15 ) , serum ( 15 ) , siRNA ( 20 ) , SP600125 ( 20 ) , TGF-beta ( 29 ) , U0126 ( 23 )

Downstream Regulation
Effects of modification on p21Cip1:	intracellular localization ( 23 ) , molecular association, regulation ( 15 , 26 ) , phosphorylation ( 15 ) , protein degradation ( 3 , 23 ) , protein stabilization ( 20 , 27 , 29 ) , ubiquitination ( 23 )
Effects of modification on biological processes:	cell cycle regulation ( 3 , 23 , 26 )
Inhibit interaction with:	CCND1 (human) ( 26 ) , CDK2 (human) ( 26 ) , CDK4 (human) ( 15 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 32645325 Curated Info
2	Colleoni B, et al. (2017) JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21. Oncogene 36, 4349-4361 28368408 Curated Info
3	Kreis NN, et al. (2016) Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation. Oncotarget 7, 50215-50228 27384476 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Rizzardi LF, et al. (2015) CDK1-dependent Inhibition of the E3 Ubiquitin Ligase CRL4CDT2 Ensures Robust Transition from S Phase to Mitosis. J Biol Chem 290, 556-67 25411249 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
8	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
13	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
14	Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
15	Bisteau X, et al. (2013) CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point. PLoS Genet 9, e1003546 23737759 Curated Info
16	Rikova K (2012) CST Curation Set: 16148; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
17	Rikova K (2012) CST Curation Set: 16146; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
18	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
19	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
20	Zhang X, et al. (2012) Neferine, an alkaloid ingredient in lotus seed embryo, inhibits proliferation of human osteosarcoma cells by promoting p38 MAPK-mediated p21 stabilization. Eur J Pharmacol 677, 47-54 22227330 Curated Info
21	Densham RM, et al. (2009) MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol 29, 6380-90 19822666 Curated Info
22	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
23	Hwang CY, Lee C, Kwon KS (2009) Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol 29, 3379-89 19364816 Curated Info
24	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
25	Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92 16964243 Curated Info
26	Järviluoma A, et al. (2006) Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 26, 2430-40 16508017 Curated Info
27	Zhu H, Nie L, Maki CG (2005) Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem 280, 29282-8 15964852 Curated Info
28	Bornstein G, et al. (2003) Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 278, 25752-7 12730199 Curated Info
29	Kim GY, et al. (2002) The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 277, 29792-802 12058028 Curated Info